This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
6 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
Acadia Healthcare (ACHC) Beats on Q2 Earnings, Ups '21 EPS View
by Zacks Equity Research
Acadia Healthcare's (ACHC) second-quarter results highlight rise in revenues, courtesy of increased volumes and facility expansions, partly offset by high costs.
Ensign Group's (ENSG) Q2 Earnings In Line, Increase Y/Y
by Zacks Equity Research
Ensign Group's (ENSG) Q2 results gain from higher revenues, cost management, and better census and managed care skilled mix across its portfolio.
Molina Healthcare (MOH) Misses on Q2 Earnings, Hikes '21 View
by Zacks Equity Research
Molina Healthcare's (MOH) Q2 earnings suffer escalating expenses. However, the same was partly offset by improved revenues and better membership.
Humana's (HUM) Q2 Earnings Surpass Estimates, Tumble Y/Y
by Zacks Equity Research
Humana's (HUM) second-quarter earnings gain from higher revenues and strong performances by its Retail and Healthcare Services segments.
3 Reasons Why Growth Investors Shouldn't Overlook HCA (HCA)
by Zacks Equity Research
HCA (HCA) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Encompass Health (EHC) Beats on Q2 Earnings, Hikes '21 View
by Zacks Equity Research
Encompass Health's (EHC) second-quarter results highlight growing revenues stemming from strong segmental performances, partly offset by elevated costs.
5 Top-Ranked Momentum Picks Using Driehaus Strategy
by Nitish Marwah
DHR, CLFD, HCA, FBP, and SNBR qualified as the day's Momentum Picks Using Driehaus Strategy.
Centene's (CNC) Q2 Earnings Miss Estimates, Improve Y/Y
by Zacks Equity Research
Centene's (CNC) second-quarter earnings gain from better revenues and membership growth.
New Strong Buy Stocks for July 27th
by Zacks Equity Research
HCA, KSS, GIL, ASIX, and CVLG have been added to the Zacks Rank #1 (Strong Buy) List on July 27, 2021.
Universal Health (UHS) Beats on Q2 Earnings, Ups '21 EPS View
by Zacks Equity Research
Universal Health's (UHS) second-quarter results reflect growing revenues attributable to strong segmental performances, partly offset by elevated expenses.
Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Earnings Growth & Price Strength Make HCA Healthcare (HCA) a Stock to Watch
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
If You Invested $1000 in HCA Healthcare 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Tenet Healthcare (THC) Beats on Q2 Earnings, Ups '21 EPS View
by Zacks Equity Research
Tenet Healthcare's (THC) second-quarter results gain on the back of higher revenues, and well-performing Hospital, Ambulatory and Conifer segments, partly offset by escalating costs.
Anthem's (ANTM) Q2 Earnings Beat Estimates, Decline Y/Y
by Zacks Equity Research
Anthem's (ANTM) Q2 earnings gain from better revenues and growth in Medicaid and Medicare business lines.
Company News for Jul 21, 2021
by Zacks Equity Research
Companies in The News Are: HCA,SYF,CFG,DOV
HCA Healthcare's (HCA) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
HCA Healthcare's (HCA) Q2 earnings gain traction from higher revenues and improved admissions.
HCA Holdings (HCA) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 37.85% and 6.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for HCA Healthcare's (HCA) Q2 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) second-quarter earnings are likely to have gained from better revenues.
Why HCA Healthcare (HCA) Might Surprise This Earnings Season
by Zacks Equity Research
HCA Healthcare (HCA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
HCA Holdings (HCA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
HCA (HCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Earnings Growth & Price Strength Make HCA Holdings (HCA) a Stock to Watch
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
HCA Healthcare (HCA) Buys 80% Stake in BHS, Boosts Network
by Zacks Equity Research
HCA Healthcare (HCA) completes purchase of majority stake in Brookdale's BHS, which has added around 80 care sites to the former's portfolio enabling it to offer enhanced healthcare services.